Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin for Bubonic Plague

PHASE3CompletedINTERVENTIONAL
Enrollment

222

Participants

Timeline

Start Date

February 15, 2020

Primary Completion Date

April 30, 2024

Study Completion Date

February 5, 2025

Conditions
Plague, BubonicPlague, Pneumonic
Interventions
DRUG

Ciprofloxacin

"Adults: Ciprofloxacin 500mg orally twice daily (or 400mg IV twice daily for those who cannot take oral medication) for 10 days;~Children:Ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 10 days.~Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician."

DRUG

Streptomycin

"Adults: streptomycin 1g twice daily for three days, followed by ciprofloxacin 500mg orally twice daily (or ciprofloxacin 400mg twice daily by IV for those unable to take orally) for an additional 7 days.~Children: streptomycin 15mg/kg twice daily for three days followed by ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 7 additional days.~Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician."

DRUG

Gentamicin

"Adults: 2.5mg/kg IV gentamicin twice daily for 3 days followed by ciprofloxacin 500 mg orally twice daily (or ciprofloxacin 400 mg twice daily IV for those who cannot take oral) for a further 7 days.~Children: 2.5mg/kg IV gentamicin twice daily for 3 days, followed by ciprofloxacin 15mg/kg (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take the oral route) for a further 7 days."

Trial Locations (1)

Unknown

Professor Mamy Randria, Antananarivo

All Listed Sponsors
collaborator

Hôpital Universitaire Joseph Raseta Befelatanana CHU d'Antananarivo

UNKNOWN

collaborator

Institut Pasteur de Madagascar

OTHER

collaborator

Foreign, Commonwealth and Development Office and Wellcome (216273.Z.19.Z)

UNKNOWN

lead

University of Oxford

OTHER

NCT04110340 - Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin for Bubonic Plague | Biotech Hunter | Biotech Hunter